The idea of producing a medicine within insect cells destined for human use may ... commercial alternative to the standard ‘triple-transfection’ AAV strategy. For example, BioMarin has used ...

Furthermore, the transfection procedures used to deliver the three plasmids to cells are robust, well-established, and can be performed at manufacturing scale. Today, at least 11 companies are ...

after transfection, the activity is rapidly cleared. CHO Plus has developed patented cell engineering technology that increases the capacity of cells to produce therapeutic proteins, and viral ...